SF3B1 and myelodysplastic syndrome: To determine the impact of XPO1 inhibition on SF3B1 mutations, we analyzed prior results from recent clinical trials of XPO1i, selinexor [22, 32] and eltanexor [34], in patients with high-risk MDS relapsed or refractory to hypomethylating agents (HMA).